PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

27 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

20 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

13 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

22 Jan 2024 16:45:19 By Nasdaq GlobeNewswire

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

16 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 Dec 2023 16:50:00 By Nasdaq GlobeNewswire

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

28 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

14 Nov 2023 07:30:55 By Nasdaq GlobeNewswire

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

09 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

07 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

23 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

11 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

02 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Present at the LD Micro Main Event XVI

26 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

25 Sep 2023 08:00:13 By Nasdaq GlobeNewswire

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

20 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

20 Sep 2023 08:00:18 By Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023

13 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire